Document Detail

Patients with recently diagnosed nonischemic cardiomyopathy benefit from implantable cardioverter-defibrillators.
MedLine Citation:
PMID:  16781376     Owner:  NLM     Status:  MEDLINE    
OBJECTIVES: This study sought to determine whether the time from diagnosis to randomization was related to outcome in a clinical trial of implantable cardioverter-defibrillator (ICD) insertion in nonischemic cardiomyopathy. BACKGROUND: Whether the duration of nonischemic cardiomyopathy is related to arrhythmic risk and the possible benefit of ICD insertion is unknown. METHODS: The Defibrillators in Nonischemic Cardiomyopathy Treatment Evaluation (DEFINITE) trial randomized 458 patients with nonischemic dilated cardiomyopathy and a left ventricular ejection fraction <36% to receive standard medical therapy with or without an ICD. Patients were randomized regardless of the duration of known cardiomyopathy as long as a reversible cause of left ventricular dysfunction was not present. Patients were divided into recently and remotely diagnosed nonischemic cardiomyopathy groups based on the time from diagnosis of cardiomyopathy to randomization. To categorize patients, cut points of three and nine months were used. RESULTS: Patients with recently diagnosed cardiomyopathy who received an ICD had better survival than those treated with standard therapy at both cut points. This difference in survival was significant at three months (p < 0.05) and was borderline significant at nine months (p = 0.058). Patients with remotely diagnosed cardiomyopathy did not have a significant survival benefit with ICD insertion, but there were no significant differences between ICD benefit in the recent and remote diagnosis groups (p = 0.17 and 0.25). CONCLUSIONS: Patients who have a recent cardiomyopathy diagnosis do not have any less ICD benefit than those with a remote diagnosis. Thus, ICD therapy should be considered in such patients as soon as they are identified as long as a reversible cause of left ventricular dysfunction is excluded.
Alan Kadish; Andi Schaechter; Haris Subacius; Emil Thattassery; William Sanders; Kelley P Anderson; Alan Dyer; Jeffrey Goldberger; Joseph Levine
Related Documents :
12142186 - Long term follow-up of surgical treatment of hypertrophic obstructive cardiomyopathy (h...
1704556 - Intravascular lead extraction using locking stylets, sheaths, and other techniques.
7845806 - Analysis of the effectiveness of in-office and transtelephonic follow-up in terms of pa...
1097836 - Cardiac function early after repair of tetralogy of fallot.
19896586 - The existence of cognitive plateaus in alzheimer's disease.
24868256 - Probiotics - a helpful additional therapy for bacterial vaginosis.
Publication Detail:
Type:  Journal Article; Randomized Controlled Trial     Date:  2006-05-30
Journal Detail:
Title:  Journal of the American College of Cardiology     Volume:  47     ISSN:  1558-3597     ISO Abbreviation:  J. Am. Coll. Cardiol.     Publication Date:  2006 Jun 
Date Detail:
Created Date:  2006-06-19     Completed Date:  2006-07-25     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  8301365     Medline TA:  J Am Coll Cardiol     Country:  United States    
Other Details:
Languages:  eng     Pagination:  2477-82     Citation Subset:  AIM; IM    
Clinical Trials Unit, Bluhm Cardiovascular Institute, Northwestern Memorial Hospital, the Division of Cardiology, Feinberg School of Medicine, Chicago, Illinois, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Cardiomyopathies / diagnosis,  mortality,  therapy*
Defibrillators, Implantable*
Middle Aged
Survival Rate
Time Factors
Comment In:
J Am Coll Cardiol. 2006 Jun 20;47(12):2483-5   [PMID:  16781377 ]

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Influence of pre-existing donor atherosclerosis on the development of cardiac allograft vasculopathy...
Next Document:  Pacing-induced increase in QT dispersion predicts sudden cardiac death following cardiac resynchroni...